Exicure Inc Stock Price, News & Analysis

Exicure (Nasdaq: XCUR) reported third quarter 2025 results for the quarter ended September 30, 2025.

Key figures: cash and cash equivalents $4.4M (Sept 30, 2025 vs $12.5M on Dec 31, 2024), R&D $0.9M, G&A $1.5M, and net loss $2.4M for Q3 2025. The company recorded a $246K loss from a contingent liability change and a $155K gain related to a self-insured retainer settlement.

Management stated cash is not sufficient to fund operations and said substantial additional financing is needed in the short term.

Exicure (Nasdaq: XCUR) announced that completed Phase 2 data for burixafor, a CXCR4 antagonist, will be presented orally at the 67th ASH Annual Meeting on December 8, 2025. The oral presentation (Abstract 1050) reports results from an open-label, multicenter Phase 2 trial (NCT05561751) of burixafor plus G-CSF and propranolol to mobilize hematopoietic progenitor cells in multiple myeloma patients undergoing autologous hematopoietic cell transplantation.

The presentation highlights an excellent safety profile, same-day administration with leukapheresis, and that 18 of 19 patients who chose transplant proceeded to AHCT; many enrolled patients had prior daratumumab exposure. Presenter: Dr. Jack Khouri. Session: Cell Collection and Manufacturing; 5:45–6:00pm EST, Hyatt Regency Ballroom R.

Exicure (Nasdaq: XCUR) reported progress on its lead program burixafor (GPC-100), highlighting that an ongoing Phase 2 multiple myeloma study achieved the primary endpoint in all evaluable patients (10/10) and that the clinical database is locked with topline data expected in Q4 2025. The company is preparing for potential Phase 3 planning and expanding development into sickle cell disease (investigator-sponsored trial discussions) and a planned Phase 1 AML chemosensitization study. Exicure also announced new senior drug-development hires to support clinical and translational execution.

Exicure (Nasdaq: XCUR) reported Q2 2025 financial results, highlighting significant challenges in its financial position. The company's cash and cash equivalents decreased to $7.9 million as of June 30, 2025, down from $12.5 million at the end of 2024.

Following the acquisition of GPCR Therapeutics USA, R&D expenses increased to $0.9 million (from $0 in Q2 2024), while G&A expenses rose to $1.5 million (from $1.2 million). The company reported a net loss of $2.6 million for Q2 2025, significantly higher than the $0.6 million loss in Q2 2024.

Management has expressed serious concerns about the company's ability to continue operations, stating that current cash reserves are insufficient and substantial additional financing is urgently needed.

Exicure (Nasdaq: XCUR), a clinical-stage biotechnology company focused on hematologic disease therapeutics, has successfully regained compliance with Nasdaq's listing requirements. The company received confirmation from Nasdaq's Listing Qualifications Department after filing its required Form 10-Q for Q1 2025.

The compliance was achieved on July 1, 2025, following the submission of periodic reports to the SEC, resolving previous filing deficiencies under Listing Rule 5250(c)(1).

Exicure (Nasdaq: XCUR) has completed the last patient visit in its Phase 2 clinical trial evaluating GPC-100 (burixafor) for stem cell mobilization in multiple myeloma patients. The study assesses GPC-100's ability to improve CD34+ hematopoietic stem cell mobilization for autologous stem cell transplant (ASCT).

Key highlights include GPC-100's differentiated rapid mobilization time of just 45 minutes before collection, compared to traditional overnight procedures. The company expects topline results in Q4 2025. Beyond multiple myeloma, Exicure plans a Phase 1 study in acute myeloid leukemia and is exploring potential collaborations for cell and gene therapy applications.

Exicure (Nasdaq: XCUR) reported Q1 2025 financial results, posting a net income of $3.0 million compared to a net loss of $0.8 million in Q1 2024. The company's cash position stood at $10.4 million as of March 31, 2025, down from $12.5 million at the end of 2024.

The quarter's performance was primarily driven by a $6 million gain from early lease termination in Chicago, offset by increased operating expenses following the GPCR USA acquisition. R&D expenses increased to $0.8 million, while G&A expenses rose to $2.2 million.

Notably, management expressed significant concern about the company's financial sustainability, stating that current cash reserves are insufficient to fund ongoing operations and substantial additional financing is urgently needed.

Exicure (NASDAQ: XCUR) has received a non-compliance notice from Nasdaq on May 21, 2025, due to failing to file its Q1 2025 Form 10-Q by the May 20, 2025 deadline. The company now has 60 calendar days to submit a compliance plan to Nasdaq. If accepted, Exicure could receive up to 180 calendar days (until November 17, 2025) to regain compliance with Nasdaq Listing Rule 5250(c)(1). The company states it is working to complete and file the Form 10-Q as soon as possible.

Exicure (NASDAQ: XCUR) has completed patient enrollment in its Phase 2 clinical trial evaluating GPC-100 (burixafor) in combination with propranolol and G-CSF for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplant. The study aims to assess if GPC-100, a CXCR4 antagonist, can enhance CD34+ hematopoietic stem cell mobilization from bone marrow to peripheral blood for collection via leukapheresis. Topline results are expected in Fall 2025.

Beyond multiple myeloma, Exicure is planning a Phase 1 chemosensitization study in relapsed/refractory acute myeloid leukemia (AML) patients. The company is also exploring GPC-100's potential in other areas requiring stem cell mobilization, including sickle cell disease, rare diseases needing autologous transplant, and cell and gene therapy applications.